Don't Buy Haleon Before Checking Its Fundamentals!

By Susan Ramirez • Tuesday, August 01 15:30 • Permanent Link

We're taking a closer look at Haleon today, as the chatter surrounding the stock has increased notably in the last few weeks. Today, its shares moved -3.1% compared to -0.0% for the S&P 500. Increased investor interest and volatility surrounding the stock are not reason enough to buy in -- you should first perform your own due diligence. Here are some figures that can get you started:

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific.
Its trailing 12 month earnings per share (EPS) is $0.31
Haleon has a trailing 12 month Price to Earnings (P/E) ratio of 27.5
The company has a Price to Book (P/B) ratio of 2.41
Haleon is part of the Consumer Discretionary sector

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.